{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:02:15Z","timestamp":1791943335191,"version":"4.3.4"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006251","name":"Universit\u00e9 de Bordeaux","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1053\/j.semnuclmed.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:18:19Z","timestamp":1754911099000},"page":"937-946","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy"],"prefix":"10.1053","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-7114","authenticated-orcid":false,"given":"Aur\u00e9lien","family":"Callaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2834-5524","authenticated-orcid":false,"given":"Heying","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2101-5626","authenticated-orcid":false,"given":"Elif","family":"Hindi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9432-9223","authenticated-orcid":false,"given":"Cl\u00e9ment","family":"Morgat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-5329","authenticated-orcid":false,"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0001","article-title":"A vision for gastrin-releasing peptide receptor targeting for imaging and therapy: Perspective from academia and industry","author":"Morgat","year":"2025","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.07.003_bib0002","doi-asserted-by":"crossref","first-page":"260","DOI":"10.2967\/jnumed.107.047167","article-title":"Gastrin-releasing peptide receptor imaging in Human breast carcinoma versus immunohistochemistry","volume":"49","author":"Van De Wiele","year":"2008","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0003","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0004","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-1119(00)00596-5","article-title":"The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter","volume":"264","author":"Xiao","year":"2001","journal-title":"Gene"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0005","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-019-04504-3","article-title":"First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer","volume":"47","author":"Kurth","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0006","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","article-title":"Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: an atlas of semi-quantitative measurements","volume":"47","author":"Baratto","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.07.003_bib0007","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2967\/jnumed.123.267017","article-title":"Prospective comparison of68 Ga-NeoB and68 Ga-PSMA-R2 PET\/MRI in patients with biochemically recurrent prostate cancer","volume":"65","author":"Duan","year":"2024","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0008","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.07.003_bib0009","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of18 F-fluoromethylcholine versus68 Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0010","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/cancers16010173","article-title":"Imaging GRPr expression in metastatic castration-resistant prostate cancer with [68Ga]Ga-RM2\u2014A head-to-head pilot comparison with [68Ga]Ga-PSMA-11","volume":"16","author":"Fern\u00e1ndez","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0011","first-page":"88","article-title":"Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts","volume":"48","author":"de Visser","year":"2007","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0012","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2967\/jnumed.115.170423","article-title":"Dose deposits from90 Y,177 Lu,111 In, and161 Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy","volume":"57","author":"Hindi\u00e9","year":"2016","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.07.003_bib0013","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.2967\/jnumed.123.265771","article-title":"Preclinical comparison of the64 Cu- and68 Ga-labeled GRPR-targeted compounds RM2 and AMTG, as well as first-in-humans [68 Ga]Ga-AMTG PET\/CT","volume":"64","author":"Koller","year":"2023","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.07.003_bib0014","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-targeted PET: results from 50 patients with biochemically recurrent prostate cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0015","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13550-020-00652-y","article-title":"Voxel-based comparison of [68Ga]Ga-RM2-PET\/CT and [68Ga]Ga-PSMA-11-PET\/CT with histopathology for diagnosis of primary prostate cancer","volume":"10","author":"Fassbender","year":"2020","journal-title":"EJNMMI Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0016","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/acsmedchemlett.3c00057","article-title":"Modular one-pot strategy for the synthesis of heterobivalent tracers","volume":"14","author":"Bailly","year":"2023","journal-title":"ACS Med Chem Lett"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0017","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2967\/jnumed.124.269189","article-title":"Additive value of [68 Ga]Ga-RM26 PET\/CT to [68 Ga]Ga-PSMA-617 PET\/CT in detecting pelvic lymph node metastasis in prostate cancer: A prospective, single-center, phase II study","volume":"66","author":"Tang","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0018","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-025-07407-8","article-title":"The additive value of 68Ga-RM26 PET\/CT to 68Ga-PSMA\u2212617 PET\/CT in assessing post-treatment outcomes of ARSIs in mCRPC patients","author":"Liu","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.07.003_bib0019","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2967\/jnumed.115.160739","article-title":"Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin Receptor 2, or Chemokine C-X-C motif Receptor 4 in breast cancer for imaging and therapy","volume":"56","author":"Dalm","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210905","article-title":"Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples. Ahmad A, \u00e9diteur","volume":"14","author":"Morgat","year":"2019","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.07.003_bib0021","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","article-title":"Expression of gastrin-releasing peptide receptor in breast cancer and its association with pathologic, biologic, and clinical parameters: a study of 1,432 primary tumors","volume":"58","author":"Morgat","year":"2017","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.07.003_bib0022","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0000000000002209","article-title":"68Ga-NOTA-RM26 PET\/CT in the evaluation of breast cancer: a pilot prospective study","volume":"43","author":"Zang","year":"2018","journal-title":"Clin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0023","doi-asserted-by":"crossref","first-page":"700","DOI":"10.2967\/jnumed.124.268896","article-title":"Diagnostic potential of68 Ga-NeoB PET\/CT with estrogen receptor\u2013 and progesterone receptor\u2013Positive breast cancer undergoing staging or restaging for metastatic disease","volume":"66","author":"Sabahi","year":"2025","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.07.003_bib0024","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.ejca.2015.05.009","article-title":"Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery","volume":"51","author":"Joensuu","year":"2015","journal-title":"Eur J Ca"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.07.003_bib0025","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00259-004-1476-2","article-title":"High expression of peptide receptors as a novel target in gastrointestinal stromal tumours","volume":"31","author":"Reubi","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.07.003_bib0026","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.3390\/biomedicines10112899","article-title":"Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients","volume":"10","author":"Gruber","year":"2022","journal-title":"Biomedicines"},{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0027","article-title":"Gastrin-releasing peptide receptor expression in gastrointestinal stromal tumours","volume":"6","author":"Berndsen","year":"2024","journal-title":"ESMO Gastrointest Oncol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.07.003_bib0028","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.2967\/jnumed.106.038091","article-title":"68Ga-Labeled Bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG","volume":"48","author":"Dimitrakopoulou-Strauss","year":"2007","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.07.003_bib0029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.124.267810","article-title":"Head-to-Head comparison of [68 Ga]Ga-NOTA-RM26 and [18 F]FDG PET\/CT in patients with gastrointestinal stromal tumors: a prospective study","volume":"66","author":"Wang","year":"2025","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5858\/arpa.2012-0679-OA","article-title":"Gastrin-releasing peptide receptor expression in lung cancer","volume":"138","author":"Mattei","year":"2014","journal-title":"Arch Pathol Laborat Med"},{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0031","series-title":"Principles and Practice of Lung Cancer: the Official Reference Text of the International Association for the Study of Lung Cancer (IASLC)","author":"Pass","year":"2010"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.07.003_bib0032","first-page":"707","article-title":"Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma","volume":"38","author":"Marrone","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"8072","key":"10.1053\/j.semnuclmed.2025.07.003_bib0033","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41586-025-09111-x","article-title":"Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin","volume":"643","author":"Raymond","year":"2025","journal-title":"Nature"},{"issue":"5\u20136","key":"10.1053\/j.semnuclmed.2025.07.003_bib0034","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000134478","article-title":"Gastrin-releasing peptide receptor expression in cervical cancer","volume":"73","author":"Cornelio","year":"2007","journal-title":"Oncology"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.07.003_bib0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.3892\/mco.2012.7","article-title":"Influence of GRPR and BDNF\/TrkB signaling on the viability of breast and gynecologic cancer cells","volume":"1","author":"Cornelio","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1126426","article-title":"Human gastrin- releasing peptide receptor expression in women with uterine cervix cancer","volume":"13","author":"Kunos","year":"2023","journal-title":"Front Oncol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0037","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00000658-200205000-00003","article-title":"Gastrin-releasing peptide is a growth factor for human neuroblastomas","volume":"235","author":"Kim","year":"2002","journal-title":"Ann Surg"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.07.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0277956","article-title":"Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma. Pizzo SV, \u00e9diteur","volume":"17","author":"Qiao","year":"2022","journal-title":"PLoS ONE"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0039","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1078-0432.CCR-07-1543","article-title":"Immunohistochemical analysis of phosphotyrosine signal transducer and activator of transcription 3 and epidermal growth factor receptor autocrine signaling pathways in head and Neck cancers and metastatic lymph nodes","volume":"14","author":"Seethala","year":"2008","journal-title":"Clin Ca Res"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.07.003_bib0040","doi-asserted-by":"crossref","first-page":"G655","DOI":"10.1152\/ajpgi.1999.276.3.G655","article-title":"Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans","volume":"276","author":"Carroll","year":"1999","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.07.003_bib0041","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s10585-009-9265-8","article-title":"Expression of GRP and its receptor is associated with improved survival in patients with colon cancer","volume":"26","author":"Rivera","year":"2009","journal-title":"Clin Exp Metastas"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.07.003_bib0042","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2967\/jnumed.124.269132","article-title":"First-in-Human serum stability studies of [177Lu]Lu-AMTG: a step toward improved GRPR-targeted radiopharmaceutical therapy","volume":"66","author":"Felber","year":"2025","journal-title":"J Nucl Med"},{"issue":"15","key":"10.1053\/j.semnuclmed.2025.07.003_bib0043","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.7150\/thno.77219","article-title":"Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors","volume":"12","author":"Jiang","year":"2022","journal-title":"Theranostics"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.07.003_bib0044","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acsmedchemlett.5c00032","article-title":"Development of novel gastrin-releasing peptide receptor-targeted radioligand with albumin binder to improve accumulation in tumor","volume":"16","author":"Tsuchihashi","year":"2025","journal-title":"ACS Med Chem Lett"},{"issue":"10446","key":"10.1053\/j.semnuclmed.2025.07.003_bib0045","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.07.003_bib0046","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.07.003_bib0047","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2967\/jnumed.123.265509","article-title":"Membrane and nuclear absorbed doses from 177Lu and 161Tb in tumor clusters: Effect of cellular heterogeneity and potential benefit of dual targeting-A Monte Carlo study","volume":"64","author":"Larouze","year":"2023","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.07.003_bib0048","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","article-title":"Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms","volume":"49","author":"Borgna","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.07.003_bib0049","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2967\/jnumed.123.266233","article-title":"Preclinical evaluation of gastrin-releasing peptide receptor antagonists labeled with 161Tb and 177Lu: a comparative study","volume":"65","author":"Holzleitner","year":"2024","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.07.003_bib0050","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2967\/jnumed.124.268101","article-title":"Preclinical investigation of [212Pb]Pb-DOTAM-GRPR1 for peptide receptor radionuclide therapy in a prostate tumor model","volume":"65","author":"Saidi","year":"2024","journal-title":"J Nucl Med"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.07.003_bib0051","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.124.267881","article-title":"Utility of64 Cu-sarcophagine-bombesin PET\/CT in men with biochemically recurrent prostate cancer and negative or equivocal findings on68 Ga-PSMA-11 PET\/CT","volume":"65","author":"Li","year":"2024","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.07.003_bib0052","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/ph15070772","article-title":"64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen\/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a phase I trial","volume":"15","author":"Wong","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.07.003_bib0053","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/ph15060728","article-title":"Copper-67-labeled bombesin peptide for targeted radionuclide therapy of prostate cancer","volume":"15","author":"Huynh","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.07.003_bib0054","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1118\/1.3608905","article-title":"Production and dosimetric aspects of the potent Auger emitter 58mCo for targeted radionuclide therapy of small tumors","volume":"38","author":"Thisgaard","year":"2011","journal-title":"Med Phys. ao\u00fbt"},{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108961","article-title":"Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: a preclinical study of the theranostic pair [55Co]Co- and [177Lu]Lu-DOTA-RM26","volume":"138-139","author":"Baun","year":"2024","journal-title":"Nucl Med Biol"},{"key":"10.1053\/j.semnuclmed.2025.07.003_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.nucmedbio.2022.03.003","article-title":"Development and biodistribution studies of 77As-labeled trithiol RM2 bioconjugates for prostate cancer: comparison of [77As]As-trithiol-ser-ser-RM2 vs. [77As]As-trithiol-glu-ser-RM2","volume":"108-109","author":"Ma","year":"2022","journal-title":"Nucl Med Biol"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000911?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825000911?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T21:45:36Z","timestamp":1761428736000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825000911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0001299825000911"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.07.003","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GRPR Expression in Metastatic Cancers: A Review of Potential Application of GRPR-Radioligand Therapy","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}